Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10669384 | 0.86 | KDM1A (0.48) | SLC6A3SLC6A4KDM1ALMNATSHR | |
| SCHEMBL10155679 | 0.80 | KDM1A (0.56) | KDM1ALMNATSHRALDH1A1 | |
| SCHEMBL28218216 | 0.78 | KDM1A (0.55) | SLC6A3KDM1ASLC6A2LMNATSHR | |
| SCHEMBL26218870 | 0.78 | KDM1A (0.54) | SLC6A3KDM1ASLC6A2LMNATSHR | |
| SCHEMBL26218874 | 0.76 | KDM1A (0.53) | SLC6A3KDM1ASLC6A2LMNATSHR | |
| SCHEMBL2817503 | 0.74 | MAOA (0.52) | SLC6A3SLC6A4DPP4SLC6A2TSHR | |
| SCHEMBL10184986 | 0.74 | TSHR (0.57) | SLC6A3KDM1ASLC6A2LMNATSHR | |
| SCHEMBL30492221 | 0.74 | KDM1A (0.50) | KDM1ALMNATSHRALDH1A1TDP1 | |
| SCHEMBL6676866 | 0.73 | AKR1C1 (0.57) | KDM1ALMNATSHRALDH1A1 | |
| SCHEMBL2814607 | 0.73 | KDM1A (0.49) | SLC6A3KDM1ASLC6A2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | SLC6A3 322/4885SLC6A4 912/4885DPP4 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.